



P R O V I D E R B U L L E T I N

B T 2 0 0 4 3 4

D E C E M B E R 2 8 , 2 0 0 4

To: All Pharmacy Providers and Prescribing Practitioners

Subject: Changes to the Preferred Drug List

Note: The information referenced below is not directed to those providers rendering services in the risk-based managed care (RBMC) delivery system.

Overview

This bulletin announces the Preferred Drug List (PDL) decisions made at the December 17, 2004, Drug Utilization Review (DUR) Board meeting. These decisions were based on the recommendations from the Therapeutics Committee meeting held on December 10, 2004. Please refer to Table 1 for a summary of these changes. **THESE CHANGES ARE EFFECTIVE JANUARY 18, 2005.**

The PDL can be accessed at www.indianapbm.com. Notice of the DUR Board meetings and agendas are posted on the Family and Social Services Administration (FSSA) Web site at <http://www.state.in.us/fssa/> under the tab titled **Calendar**. Information about the Therapeutics Committee and the PDL is available at <http://www.indianapbm.com>.

Please direct prior authorization requests and questions regarding the PDL to the ACS Clinical Call Center at 1-866-879-0106. Questions about this bulletin should be directed to the ACS Pharmacy Services Helpdesk at 1-866-645-8344.

Table 1 – Approved Changes to the PDL Effective January 18, 2005

Drug Class	Drug	PDL Status
Beta Agonists	Xopenex	Preferred (quantity limit of 2 prescriptions per 6 months, 1 box of 24 per prescription)
Bone Resorption Suppression Agents	Fosamax	All formulations Preferred
Bone Resorption Suppression Agents	Actonel	Moved to Non-Preferred; step therapy required (Patient must have been on Fosamax within the previous 180 days)